Bioventix (BVXP) - Total Assets
Based on the latest financial reports, Bioventix (BVXP) holds total assets worth GBX13.03 Million GBX (≈ $1.59K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bioventix - Total Assets Trend (2006–2025)
This chart illustrates how Bioventix's total assets have evolved over time, based on quarterly financial data. Also see Bioventix stock valuation for the company's overall valuation and market capitalisation.
Bioventix - Asset Composition Analysis
Current Asset Composition (June 2025)
Bioventix's total assets of GBX13.03 Million consist of 93.5% current assets and 6.5% non-current assets. Review Bioventix debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (GBX) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 39.5% |
| Accounts Receivable | GBX6.24 Million | 48.5% |
| Inventory | GBX689.40K | 5.4% |
| Property, Plant & Equipment | GBX0.00 | 0.0% |
| Intangible Assets | GBX0.00 | 0.0% |
| Goodwill | GBX0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Bioventix's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See BVXP live share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bioventix's current assets represent 93.5% of total assets in 2025, an increase from 0.0% in 2006.
- Cash Position: Cash and equivalents constituted 39.5% of total assets in 2025, up from 20.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 21.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 48.5% of total assets.
Bioventix Competitors by Total Assets
Key competitors of Bioventix based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Abivax SA
PA:ABVX
|
France | €547.14 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Braveheart Bio, Inc. Common Stock
NASDAQ:BRVE
|
USA | $126.96 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Lifecome Biochemistry Co Ltd
SHE:002868
|
China | CN¥729.16 Million |
|
Pulike Biological Engineering
SHG:603566
|
China | CN¥3.09 Billion |
|
Rocket Pharmaceuticals Inc
NASDAQ:RCKT
|
USA | $423.10 Million |
|
NEWRON PHARMACEUT. EO-20
XETRA:NP5
|
Germany | €40.03 Million |
Bioventix - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.12 | 7.01 | 11.69 |
| Quick Ratio | 5.76 | 6.69 | 11.42 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | GBX10.20 Million | GBX10.41 Million | GBX8.98 Million |
Bioventix - Advanced Valuation Insights
This section examines the relationship between Bioventix's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.67 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -6.3% |
| Total Assets | GBX12.86 Million |
| Market Capitalization | $985.36K USD |
Valuation Analysis
Below Book Valuation: The market values Bioventix's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Bioventix's assets decreased by 6.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Bioventix (2006–2025)
The table below shows the annual total assets of Bioventix from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | GBX12.86 Million ≈ $1.57K |
-6.32% |
| 2024-06-30 | GBX13.73 Million ≈ $1.67K |
+3.38% |
| 2023-06-30 | GBX13.28 Million ≈ $1.62K |
+1.25% |
| 2022-06-30 | GBX13.12 Million ≈ $1.60K |
+1.63% |
| 2021-06-30 | GBX12.91 Million ≈ $1.57K |
-2.95% |
| 2020-06-30 | GBX13.30 Million ≈ $1.62K |
+14.52% |
| 2019-06-30 | GBX11.61 Million ≈ $1.41K |
-2.21% |
| 2018-06-30 | GBX11.88 Million ≈ $1.44K |
+14.40% |
| 2017-06-30 | GBX10.38 Million ≈ $1.26K |
+18.30% |
| 2016-06-30 | GBX8.78 Million ≈ $1.07K |
+27.14% |
| 2015-06-30 | GBX6.90 Million ≈ $839.77 |
+19.68% |
| 2014-06-30 | GBX5.77 Million ≈ $701.69 |
+27.81% |
| 2013-06-30 | GBX4.51 Million ≈ $549.00 |
+26.99% |
| 2012-06-30 | GBX3.55 Million ≈ $432.33 |
+23.89% |
| 2011-06-30 | GBX2.87 Million ≈ $348.95 |
+12.60% |
| 2010-06-30 | GBX2.55 Million ≈ $309.90 |
+7.06% |
| 2009-06-30 | GBX2.38 Million ≈ $289.46 |
+69.08% |
| 2008-06-30 | GBX1.41 Million ≈ $171.19 |
+46.56% |
| 2007-06-30 | GBX960.00K ≈ $116.80 |
-6.52% |
| 2006-06-30 | GBX1.03 Million ≈ $124.96 |
-- |
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flo… Read more